Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
ILR-H82F4 | Human | Biotinylated Human IL-4 R alpha / CD124 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILR-H5253 | Human | Human IL-4 R alpha / CD124 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILR-H82E9 | Human | Biotinylated Human IL-4 R alpha / CD124 Protein, Avitag™,His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
ILR-M5252 | Mouse | Mouse IL-4 R alpha / CD124 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILR-M52H1 | Mouse | Mouse IL-4 R alpha / CD124 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILR-C52H8 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque IL-4 R alpha / CD124 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILR-C5258 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque IL-4 R alpha / CD124 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
ILR-H5221 | Human | Human IL-4 R alpha / CD124 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human IL-4, Tag Free (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well)can bind Human IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253) with a linear range of 1-20 ng/mL (QC tested).
The purity of Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) is more than 90% and the molecular weight of this protein is around 120-147 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Dupilumab | SAR-231893; REGN-668 | Approved | Sanofi, Regeneron Pharmaceuticals Inc | 达必妥, Dupixent | Mainland China | Dermatitis, Atopic | Sanofi-Aventis Group | 2017-03-28 | Asthma; Hypersensitivity; Dermatitis, Atopic; Peanut Hypersensitivity; Hypersensitivity, Immediate; Keratoconjunctivitis; Pulmonary Disease, Chronic Obstructive; Prurigo; Sinusitis; Pemphigoid, Bullous; Urticaria; Neurodermatitis; Aspergillosis, Allergic Bronchopulmonary; Rhinitis, Allergic; Eosinophilic Esophagitis; Skin Diseases, Eczematous; Skin Diseases; Genetic Diseases, Inborn; Dermatitis; Nasal Polyps; Respiration Disorders; Chronic Urticaria; Meningitis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian) | 611 | Phase 2 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Dermatitis, Atopic | Details |
CBP-201 | CBP-201 | Phase 2 Clinical | Suzhou Conrad Biomedicine Co Ltd | Nose Diseases; Nasal Polyps; Status Asthmaticus; Asthma; Sinusitis; Dermatitis, Atopic | Details |
Recombinant humannized monoclonal antibody (Connaught Biomedical Technology) | CM-310 | Phase 2 Clinical | Keymed Biosciences Co Ltd, CSPC Pharmaceutical Group Ltd | Nose Diseases; Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic | Details |
SHR-1819 | SHR-1819 | Phase 1 Clinical | Atridia Pty Ltd | Asthma; Dermatitis, Atopic | Details |
PRS-060 | PRS-060; AZD-1402; PRS-060/AZD1402 | Phase 2 Clinical | Pieris Pharmaceuticals, University Of Melbourne | Asthma | Details |
LQ-036 | LQ-036 | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
QX-005N | QX-005N | Phase 2 Clinical | Jiangsu Quanxin Biomedical Co Ltd | Chronic Urticaria; Sinusitis; Dermatitis, Atopic | Details |
MG-K10 | MG-010; MG-K-10; MG-K10 | Phase 1 Clinical | Shanghai Mabgeek Biotechnology Co Ltd, Dragonboat Biopharmaceutical | Asthma; Dermatitis, Atopic | Details |
MG-D-1609 | MG-D-1609 | Phase 2 Clinical | Metagone Biotech | Solid tumours | Details |
Manfidokimab | AK-120 (Akeso ) | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Asthma; Dermatitis, Atopic | Details |
This web search service is supported by Google Inc.